Clinical Trial Update: A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GSK1349572 (dolutegravir) to raltegravir in antiretroviral-experienced, integrase inhibitor-naive adults; completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GSK1349572
• Raltegravir (raltegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-01-31